Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-5001 for adenovirus ARD in military recruits
NCT00382408Phase 3Completed
- Sponsor
- Duramed Research
- Start
- Sep 2006
- Primary completion
- Dec 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adenovirus type 4 vaccine, live + adenovirus type 7 vaccine, live in adenoviral infection (2 arms), sponsored by Duramed Research. Primary endpoints: Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- ITT Cohort, Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort and 2 more. Started Sep 2006; status: completed.
02
Drugs
adenovirus type 4 vaccine, live + adenovirus type 7 vaccine, live
03
Conditions
adenoviral infection
Beyond the preview
Go deeper on NCT00382408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382408.